Form 8-K

8-K — Nexalin Technology, Inc.

Accession: 0001829126-26-005453

Filed: 2026-05-19

Period: 2026-05-14

CIK: 0001527352

SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)

Item: Entry into a Material Definitive Agreement

Item: Unregistered Sales of Equity Securities

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — nexalintec_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (nexalintec_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: nexalintec_8k.htm · Sequence: 1

false

0001527352

2026-05-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 14, 2026

NEXALIN TECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41507

27-5566468

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1776 Yorktown, Suite 550, Houston, Texas

77056

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone

number, including area code: (832) 260-0222

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

NXL

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01

Entry into a Material Definitive Agreement.

Stock Purchase Agreement

On May 14, 2026, Nexalin Technology, Inc. (the “Company”)

entered into a Stock Purchase Agreement (the “Purchase Agreement”) with GreenLight Ventures LLC, a North Carolina limited

liability company (“GLV”). Pursuant to the Purchase Agreement, the Company purchased from GLV, 100 shares (the “PONM

Shares”) of common stock, no par value, of PONM, Inc., a North Carolina corporation (“PONM”), representing all of the

issued and outstanding shares of PONM.

As consideration for the PONM Shares, the Company agreed to issue to

GLV shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), with an aggregate value of $1.3

million (such shares, the “Consideration Shares”). The number of Consideration Shares issuable under the Purchase Agreement

will based on the volume-weighted average price per share of the Common Stock on The Nasdaq Capital Market for the 30 trading days ending

on the trading day prior to the closing date, as noted below.

The Consideration Shares are issuable in four tranches: 45% at closing;

20%, on the date that is 90 days after the closing date; 20%, on the date that is 180 days after the closing date; and 15%, on the date

that is 270 days after the closing date. Closing of the first tranche under the Purchase Agreement occurred, and the Company issued the

initial tranche of the Consideration Shares, or 959,016 shares of Common Stock, on May 14, 2026 (the “Closing Date”). The

unissued Consideration Shares are subject to specified protective provisions prior to issuance of the final tranche, including down-round

protection for certain issuances below the applicable per share price, equitable adjustment for stock splits, reverse stock splits, recapitalizations,

reclassifications and similar capital adjustments, and delisting protection, in each case, subject to a floor of $0.61 per share and a

ceiling of $1.15 per share. The Purchase Agreement also provides for an acceleration of the issuance of all remaining unissued Consideration

Shares upon a change of control of the Company.

By acquiring PONM pursuant to the Purchase Agreement, the Company,

through PONM, secured the benefit of PONM’s exclusive license to certain of GLV’s software and platform technology supporting

the Company’s HALO™ Clarity program and NeuroCare™ virtual clinic (the “PONM Field of Use”).

The foregoing description of the Purchase Agreement does not purport

to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, a copy of which will be filed

with the Securities and Exchange Commission (the “SEC”) as an exhibit to the Company’s Quarterly Report on Form 10-Q

for the quarter ended June 30, 2026.

Collaboration Agreement

On May 14, 2026, the Company entered into a Collaboration Agreement

(the “Collaboration Agreement”) with GLV to support the development, compliance and commercialization of the Company’s

cranial electrotherapy stimulation technologies and related products using certain licensed software associated with GLV’s digital

technology platforms. Prior to the Company’s entry into the Purchase Agreement and the Collaboration Agreement, GLV and PONM entered

into a License Agreement, dated April 30, 2026 (the “License Agreement”), under which PONM obtained an exclusive license to

use certain GLV software within the PONM Field of Use.

Under the Collaboration Agreement, GLV will provide development services

under schedules of work and, upon request, infrastructure support services. Unless otherwise specified in a schedule of work, the Company

will pay GLV $10,000 per month for such development services, with approved excess development services and approved infrastructure support

services billed at rates set forth in the Collaboration Agreement.

The Collaboration Agreement has an initial term of 24 months and may

be terminated by either party upon 180 days’ written notice or for an uncured material breach. If GLV is the breaching party, the

Company is released from certain payment obligations for work not received or accepted and retains rights and licenses in software developed

by GLV during paid service allotments.

The Collaboration Agreement provides that each party retains its background

intellectual property. GLV owns improvements to the licensed software created by GLV or jointly with the Company or a third party during

the term, and grants the Company a exclusive, perpetual, irrevocable, worldwide, royalty-free, sublicensable license to use such intellectual

property solely within the PONM Field of Use.

The foregoing description of the Collaboration Agreement does not purport

to be complete and is qualified in its entirety by reference to the full text of the Collaboration Agreement, a copy of which will be

filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended

June 30, 2026.

Item

3.02

Unregistered Sales of Equity Securities.

The disclosure set forth in Item 1.01 above is incorporated by reference

into this Item 3.02.

The Consideration Shares, including the 959,016 shares of Common Stock

issued to GLV on the Closing Date, have been or will be issued in reliance on the exemption from registration under the Securities Act

of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated

thereunder.

Item

8.01

Other

Events.

May 19, 2026, the Company issued a press release announcing the transactions described in Item 1.01 of this Current Report, including

its acquisition of PONM Shares and entry into the Purchase Agreement and the Collaboration Agreement. A copy of the press release is attached

as Exhibit 99.1 to this Current Report.

Item 9.01

Financial Statements and Exhibits.

Exhibit No.

Description

99.1

Press Release, dated May 19, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly

authorized.

Date: May 19, 2026

NEXALIN TECHNOLOGY, INC.

/s/ Mark White

Mark White

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: nexalintec_ex99-1.htm · Sequence: 2

Exhibit 99.1

FOR IMMEDIATE RELEASE

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture and virtual-care infrastructure already deployed at UCSD

HOUSTON, TX, May 19, 2026, Nexalin Technology, Inc. (Nasdaq: NXL) (“Nexalin” or the “Company”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the closing of its acquisition of PONM, Inc. (“PONM”) from GreenLight Ventures, LLC (“GreenLight”). PONM is the digital health platform supporting Nexalin’s HALO™ Clarity program and Nexalin NeuroCare™ virtual clinic.

Through the transaction, Nexalin has secured ownership of PONM and an exclusive license to the proprietary software features developed for the HALO™ program, including AI-integrated remote patient monitoring, treatment-compliance data capture, electronic health record functionality, virtual-clinic management, real-time clinical-data analysis and analytics capabilities. The technology is already deployed at the University of California, San Diego (“UCSD”), where it supports HALO™ headset usage tracking, remote prescribing, physician oversight and clinical research workflows.

The acquisition gives Nexalin greater control over a critical layer of its HALO™ Clarity ecosystem: the digital infrastructure that connects the device, the patient, the prescribing physician and the clinical-data workflow. Nexalin believes this integrated device-plus-software model is important to the Company’s planned pivotal trial, future regulatory strategy and potential commercial deployment of HALO™ Clarity as an at-home, physician-supervised therapy. The platform is designed to use AI-enabled tools to support real-time data capture, treatment-adherence monitoring, protocol compliance and physician oversight across clinical research and future patient-management workflows.

At UCSD, phases one through five of the Nexalin NeuroCare™ virtual clinic have been deployed to support patient recruitment, AI-integrated monitoring and clinical-data workflows for Nexalin’s TBI/PTSD military study, and are being readied to support the Company’s planned 160-participant FDA pivotal trial of HALO™ Clarity for moderate-to-severe insomnia, with enrollment expected to begin in Q2 2026.

In connection with the transaction, GreenLight has become a meaningful equity holder in Nexalin, aligning the parties around the long-term success of HALO™ Clarity, Nexalin NeuroCare™ and the Company’s broader neurostimulation platform.

As part of the broader transaction structure, Nexalin and GreenLight have entered into a strategic partnership that provides Nexalin with continued access to GreenLight’s product, engineering, quality assurance, cybersecurity, regulatory, behavioral-health and commercial-development capabilities.

“This acquisition gives Nexalin ownership of a critical part of the HALO™ Clarity ecosystem: the digital platform that connects the device, the patient, the physician and the clinical-data workflow,” said Mark White, Chief Executive Officer of Nexalin Technology. “The PONM platform is already deployed at UCSD and supports the AI-integrated remote-monitoring, clinical-data capture and virtual-clinic capabilities we believe are essential to scaling HALO™ Clarity. By bringing this infrastructure under Nexalin ownership, we are strengthening our ability to execute through pivotal trial activities, planned FDA submission and potential commercial launch. We believe combining HALO™ Clarity with AI-enabled data infrastructure can strengthen treatment oversight, improve protocol adherence and create a scalable foundation for future physician-supervised, at-home neurostimulation programs.”

“We

believe the future of neurostimulation will be defined not only by the device itself, but by the software, data and physician-supervised

care model around it,” continued Mr. White. “This transaction strengthens Nexalin’s control over that full ecosystem

and expands what we believe the Company can ultimately offer to patients and providers seeking non-invasive treatment alternatives.”

“GreenLight

has spent years building digital infrastructure for next-generation healthcare technologies, and HALO™ Clarity is exactly the type

of platform our work was designed to support,” said Peter Gratale, Founder of GreenLight Ventures. “With this transaction,

Nexalin has the exclusive rights to the platform, while GreenLight remains aligned as both a long-term partner and shareholder. Under

our strategic partnership, GreenLight’s broader product, engineering, regulatory, clinical and commercial capabilities will remain

available to support HALO™ Clarity through pivotal trial execution, regulatory submission and potential commercial launch.”

Total consideration for the transaction is $1.3 million, payable in shares of Nexalin common stock issued in tranches over time at prices tied to Nexalin’s market performance. Nexalin believes this structure aligns GreenLight’s economics with the long-term success of the HALO™ Clarity and Nexalin NeuroCare™ programs.

Nexalin believes the transaction strengthens its ability to integrate device, software, AI-enabled remote monitoring and clinical-data infrastructure under a unified platform designed to support HALO™ Clarity through clinical development, regulatory submission and planned commercialization.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. Nexalin’s medical devices are non-invasive and undetectable to the human body. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders, and that the deeper-penetrating waveform in its next-generation devices, including the HALO™ Clarity, will generate enhanced patient response without adverse side effects. The Nexalin Gen-2 SYNC 15 milliamp neurostimulation device has been approved in China, Brazil, Oman, and Israel. Additional information is available at www.nexalin.com.

About PONM

PONM is a digital health platform built to power next-generation healthcare technologies. Its software supports clinical data capture, remote patient monitoring, electronic health records, telehealth workflows, medical device connectivity, and AI-driven clinical insights, used in clinical research, patient management programs, and connected medical device ecosystems. Following closing, PONM operates as a wholly owned subsidiary of Nexalin Technology, Inc., with its platform fully integrated into Nexalin’s HALO™ Clarity program.

About GreenLight Ventures, LLC

GreenLight

Ventures is a North Carolina-based developer of digital health infrastructure, partnering with healthcare technology companies to build

software systems that connect patients, clinicians, and connected medical devices through secure, regulatory-grade platforms. Following

the PONM transaction, GreenLight is a long-term strategic partner and equity holder in Nexalin Technology, Inc.

FORWARD-LOOKING STATEMENTS

This

press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933,

as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of

1995 (the “PSLRA”). These forward-looking statements relate to future events, future performance, or management’s current

expectations, beliefs, assumptions, plans, estimates, intentions, or projections relating to the future, and are not guarantees of future

performance. Any statements that are not statements of historical fact, or that refer to expectations, projections, or other characterizations

of future events or circumstances (including, without limitation, statements containing the words “believes,” “expects,”

“anticipates,” “plans,” “intends,” “will,” “may,” “could,” “should,”

“would,” “designed to,” “positioned to,” “potential,” “targeted,” “seeking,”

“continues,” “strategy,” “opportunity,” “estimates,” “projects,” “forecasts,”

“predicts,” “outlook,” “guidance,” or similar expressions, or the negative of such terms), are forward-looking

statements. These statements are based on Nexalin’s current expectations, assumptions, and beliefs and are subject to a number

of risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or

implied by the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which

speak only as of the date of this press release.

Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected benefits, significance, strategic rationale, and potential implications of the PONM acquisition and the GreenLight strategic partnership; the integration, capabilities, operation, deployment, and potential use of PONM, HALO™ Clarity, Nexalin NeuroCare™, and related AI-integrated remote patient monitoring, clinical-data capture, electronic health record, virtual-clinic, analytics, cybersecurity, regulatory, quality assurance, and commercial-development capabilities; the design, enrollment, timing, progress, results, and potential outcomes of the HALO™ Clarity pivotal program and other future clinical trials; the potential for future development, regulatory progress (including any planned De Novo FDA submission), and commercialization of the Company’s products and technology; the Company’s beliefs regarding its competitive position, market opportunity, value proposition, and anticipated patient, provider, clinical, and commercial benefits; the timing and issuance of transaction consideration; management’s expectations regarding future regulatory submissions, clearances, approvals, and regulatory strategy; and the Company’s strategic plans, business prospects, financial and operating performance, and capital needs. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that may cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. No assurance can be given that the anticipated benefits of the transaction or strategic partnership will be realized, that future studies will be initiated or completed on a timely basis or at all, that the Company’s technology will receive regulatory clearance or approval for any particular indication or on any anticipated timeline, or that the Company will be able to commercialize its products or technology.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the Company’s control. Such risks include, but are not limited to: the Company’s ability to successfully integrate, maintain, secure, validate, and scale PONM and related AI-integrated, data, software, and clinical-workflow systems; the ability to realize the anticipated benefits of the PONM acquisition and GreenLight strategic partnership; uncertainties regarding the design, enrollment, execution, timing, results, and completion of clinical trials, including the HALO™ Clarity pivotal program; the ability to obtain regulatory clearance or approval from the U.S. Food and Drug Administration (the “FDA”) or other regulatory bodies, including with respect to any planned De Novo submission; the sufficiency of clinical and non-clinical data to support regulatory submissions; changes in FDA, healthcare, data privacy, cybersecurity, and other applicable regulatory requirements; the potential for adverse events, safety concerns, or product performance issues; market acceptance of, and reimbursement for, the Company’s products; the Company’s ability to protect and enforce its intellectual property rights; competition from existing and new treatment alternatives; the Company’s reliance on GreenLight, UCSD, third-party manufacturers, suppliers, clinical investigators, technology vendors, and other third parties; the Company’s ability to secure adequate funding on acceptable terms to complete its planned clinical, regulatory, and commercial programs; potential dilution or market effects from equity issuances and share price volatility; and general economic, political, regulatory, industry, and market conditions. Additional risks and uncertainties that could cause actual results to differ materially are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, and in the Company’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings the Company makes from time to time with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these filings are available free of charge on the SEC’s website at www.sec.gov and on the Company’s investor relations website. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all such risks or to assess the impact of all such risks on its business or the extent to which any risk, or combination of risks, may cause actual results to differ materially from those contained in any forward-looking statements.

All forward-looking statements in this press release are qualified in their entirety by this cautionary statement and the risk factors and other disclosures referenced above, and speak only as of the date they are made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances, or otherwise, after the date of this press release.

Contact:

Crescendo Communications, LLC

Tel: (212) 671-1020

Email: NXL@crescendo-ir.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 14, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 14, 2026

Entity File Number

001-41507

Entity Registrant Name

NEXALIN TECHNOLOGY, INC.

Entity Central Index Key

0001527352

Entity Tax Identification Number

27-5566468

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1776 Yorktown

Entity Address, Address Line Two

Suite 550

Entity Address, City or Town

Houston

Entity Address, State or Province

Entity Address, Postal Zip Code

77056

City Area Code

(832)

Local Phone Number

260-0222

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

NXL

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration